Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TVGN Tevogen Bio Holdings

Closed 12-05 16:00:00 EST

0.4006

-0.0211

-5.00%

盘后0.4100

+0.0094+2.35%

19:00 EST

High0.4480	Low0.4000	Vol328.07K
Open0.4331	D1 Closing0.4217	Amplitude11.38%
Mkt Cap79.60M	Tradable Cap9.84M	Total Shares198.69M
T/O136.07K	T/O Rate1.34%	Tradable Shares24.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":0.4006,"timestamp":1764968400000,"preClose":0.4217,"halted":0,"volume":328068,"hourTrading":{"tag":"盘后","latestPrice":0.41,"preClose":0.4006,"latestTime":"19:00 EST","volume":6653,"amount":2700.6689,"timestamp":1764979242427},"delay":0,"floatShares":24551700,"shares":198689921,"eps":-0.188139,"marketStatus":"Closed","change":-0.0211,"latestTime":"12-05 16:00:00 EST","open":0.4331,"high":0.448,"low":0.4,"amount":136073.52875844002,"amplitude":0.113825,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.188139,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":0.4217,"preHourTrading":{"tag":"盘前","latestPrice":0.4509,"preClose":0.4217,"latestTime":"09:29 EST","volume":3328,"amount":1474.7828992,"timestamp":1764944947022},"postHourTrading":{"tag":"盘后","latestPrice":0.41,"preClose":0.4006,"latestTime":"19:00 EST","volume":6653,"amount":2700.6689,"timestamp":1764979242427},"volumeRatio":0.97337},"requestUrl":"/m/hq/s/TVGN","defaultTab":"news","newsList":[{"id":"2584134477","title":"Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584134477","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584134477?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:23","pubTimestamp":1763644980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2025 08:23 ET (13:23 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0},{"id":"2583682607","title":"Top News Today: Stocks Mixed as AI Selloff Slows","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682607?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:45","pubTimestamp":1763156700,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields rose amid doubts about the Federal Reserve's next move.COMMODITIES: Oil futures rose after Ukraine drone attacks on a Russian Black Sea port.Walmart picked one of its longtime executives, John Furner, to become its next chief executive, preserving its tradition of promoting an insider to steer the nation's biggest retailer. The 51-year-old Furner was seen inside the company as the likely heir apparent and ready for his next step after six years leading Walmart's U.S. business. Outside the company, the Walmart veteran-and son of a Walmart executive-was seen as a potential CEO candidate for other firms too.The reopened federal government will on Thursday release the first backlogged monthly jobs report, for the month of September. And a flood of other data is due to start flowing soon.They promised investments in the U.S. that would reduce Switzerland's trade imbalance with the U.S., according to people familiar wit","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRC","LU1430594728.SGD","LU2430703178.SGD","SRG","JJSF","XP","IPAR","BK4007","KALA","RHEP","BK4152","LITS","IIIV","OTLC","LWLG","PRPO","BK4561","LU2430703251.USD","TVGN","ASPI","GPUS","TORM","BK4211","AAME","LFMD","UAVS","PNBK","BYFC","ALTS","LU2468319806.SGD","HP","ARMK","LU0203347892.USD","ELDN","MRK","SPRB","STI","LU2592432038.USD","LU0061474960.USD","LU2361044865.SGD","LU2750360641.GBP","WMT","IE00B2B36J28.USD","LU0861579265.USD","LU1066053197.SGD","LU2023250843.SGD","ALBT","NWBO","LU1974910355.USD"],"gpt_icon":0},{"id":"2583686771","title":"Press Release: Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q","url":"https://stock-news.laohu8.com/highlight/detail?id=2583686771","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583686771?lang=en_us&edition=fundamental","pubTime":"2025-11-15 03:32","pubTimestamp":1763148720,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Nov. 14, 2025  -- Tevogen  , today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, 2025, highlighting continued capital-efficient execution at a time when sustainability has become what the Company believes a defining challenge for the biotechnology industry.Tevogen reported a loss from operations calculated in accordance with U.S. GAAP of $5.7 million for the three months ended September 30, 2025, a reduction of 6% as compared to the three months ended September 30, 2024. The Company reported a 51% reduction in operating loss, totaling $21.5 million for the nine months ended September 30, 2025, compared to the same period in 2024.Tevogen Bio Holdings Inc. Unaudited Consolidated Statements of Operations. development      $ 3,110,752   $ 3,260,938   $  9,005,811   $ 28,196,970. The following tables present adjusted loss from operation, which is a non-GAAP financial measure that we define as loss from operations excluding stock-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2581706471","title":"Tevogen announces clinical milestone in evolution of ExacTcell platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2581706471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581706471?lang=en_us&edition=fundamental","pubTime":"2025-11-06 04:25","pubTimestamp":1762374358,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) announced a clinical milestone in the evolution of its proprietary ExacTcell platform: completion of T cell target identification fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-announces-clinical-milestone-in-evolution-of-exactcell-platform-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-announces-clinical-milestone-in-evolution-of-exactcell-platform-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2581706505","title":"Tevogen Bio Expands Precision T Cell Therapy Eligibility With Multi-HLA Targeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581706505","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581706505?lang=en_us&edition=fundamental","pubTime":"2025-11-06 04:20","pubTimestamp":1762374018,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. has announced a significant clinical milestone in the development of its investigational precision T cell therapy, TVGN 489, designed for the treatment of acute and Long COVID. The company has completed T cell target identification for an additional five human leukocyte antigen  restrictions, broadening patient eligibility for its therapy. This advancement builds on a previously completed clinical trial of TVGN 489, which demonstrated 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patients. Results from this initial proof-of-concept trial were published in Blood Advances. TVGN 489 utilizes off-the-shelf, genetically unmodified allogeneic T cells and aims to expand therapeutic access regardless of patients' genetic backgrounds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for info","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL3blB8C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4588","IE00BGHQF748.EUR","BK4139","LU2210149790.SGD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","TVGN","LU2095319765.USD","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2581706587","title":"Tevogen Reports Major Clinical Milestone: Expands Hla Coverage of Its Investigational Precision T Cell Therapy for Acute and Long Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2581706587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581706587?lang=en_us&edition=fundamental","pubTime":"2025-11-06 04:20","pubTimestamp":1762374000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA9RJPJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"2580247844","title":"Tevogen Bio Says Stockholders' Deficit is Under $9.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2580247844","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580247844?lang=en_us&edition=fundamental","pubTime":"2025-11-04 04:16","pubTimestamp":1762200960,"startTime":"0","endTime":"0","summary":"Tevogen Bio said its total stockholders' deficit is less than $9.5 million, despite including in financial statements that it had an accumulated deficit of $129 million.The biotechnology company's financial statements presented for the quarter ended June 30 showed a deficit of $129 million, but with certain adjustments, that amount falls below $9.5 million, Chief Financial Officer Kirti Desai said Monday.Backing out the cash balance, the total cash loss to date is a little over $41 million and the remaining balance represents non-cash expenses of about $88 million. That is further offset by a credit of $110 million in additional paid-in capital. The company is also factoring in a capital raise amount of more than $8.8 million.Tevogen had raised total cash of under $42 million as of June 30.Tevogen plans to share a clearly labeled, fully reconciled set of adjusted financial metrics following its third-quarter filing, it said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2580242570","title":"Tevogen Bio Holdings Inc - Gaap Financials for Qtr Show $129 Mln Accumulated Deficit","url":"https://stock-news.laohu8.com/highlight/detail?id=2580242570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580242570?lang=en_us&edition=fundamental","pubTime":"2025-11-04 03:46","pubTimestamp":1762199161,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nFWN3WF249:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"2575756840","title":"BRIEF-Tevogen Says Actively Preparing For Next Stage Of Development Of TVGN 489","url":"https://stock-news.laohu8.com/highlight/detail?id=2575756840","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575756840?lang=en_us&edition=fundamental","pubTime":"2025-10-16 03:56","pubTimestamp":1760558182,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Says Actively Preparing For Next Stage Of Development Of TVGN 489Oct 15 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN BIO HOLDINGS INC - TO COLLABORATE TO EXPEDITE DEVELOPMENT OF T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nFWN3VW2DR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"2575375688","title":"Tevogen: Intends to Collaborate With Govt Initiatives, Long Covid Patient Organizations, Healthcare Providers to Expedite Development of Tvgn 489","url":"https://stock-news.laohu8.com/highlight/detail?id=2575375688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575375688?lang=en_us&edition=fundamental","pubTime":"2025-10-16 03:52","pubTimestamp":1760557947,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nFWN3VW2DR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2575002755","title":"Tevogen Bio Holdings: Actively Preparing for Next Stage of Development of Tvgn 489","url":"https://stock-news.laohu8.com/highlight/detail?id=2575002755","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575002755?lang=en_us&edition=fundamental","pubTime":"2025-10-16 03:52","pubTimestamp":1760557947,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nFWN3VW2DR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2575755006","title":"Tevogen Bio Announces Positive Safety Results from TVGN 489 Clinical Trial for Long COVID, Plans Next Development Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2575755006","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575755006?lang=en_us&edition=fundamental","pubTime":"2025-10-16 03:50","pubTimestamp":1760557814,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. has provided an update on its investigational precision T cell therapy, TVGN 489, which is under development for the treatment of COVID-19 and Long COVID. The company reported that its dose-finding clinical trial of TVGN 489 demonstrated a favorable safety profile, and the results have been peer-reviewed and published in Blood Advances, the journal of the American Society of Hematology. TVGN 489 is not yet available for broader clinical use. Tevogen is preparing for the next phase of development and intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite further development and potential patient access, pending regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL5bcYSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4139","LU0314104364.USD","NDAQ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","TVGN","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4585","BK4588","LU2095319765.USD","LU2210150020.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2575813756","title":"Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2575813756","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575813756?lang=en_us&edition=fundamental","pubTime":"2025-10-16 03:50","pubTimestamp":1760557800,"startTime":"0","endTime":"0","summary":"Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of pat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/15/3167452/0/en/Tevogen-Updates-on-TVGN-489-Following-Growing-Long-COVID-Patient-Interest.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2570830309","title":"Tevogen Bio Receives Nasdaq Notice for Non-Compliance With $1 Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2570830309","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570830309?lang=en_us&edition=fundamental","pubTime":"2025-09-27 05:16","pubTimestamp":1758921389,"startTime":"0","endTime":"0","summary":"**Tevogen Bio Holdings Inc. Receives Nasdaq Non-Compliance Notice** Tevogen Bio Holdings Inc. announced that it has received a notice from the Nasdaq Stock Market indicating that the company is not in compliance with the Nasdaq's minimum bid price requirement of $1.00 per share. The notice, received on September 23, 2025, was issued after the company's common stock traded below $1.00 for 30 consecutive business days. Tevogen Bio has 180 calendar days, until March 23, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The company may be eligible for an additional 180-day compliance period if certain conditions are met. Tevogen Bio stated that it is monitoring the situation and evaluating options, but there is no assurance it will regain compliance or maintain its Nasdaq listing. The notice does not immediately affect the company's listing or trading on the Nasdaq Global Market.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL3fp7rD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2569718320","title":"Tevogen highlights potential role of TVGN 489 on impact of Long COVID","url":"https://stock-news.laohu8.com/highlight/detail?id=2569718320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569718320?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:35","pubTimestamp":1758630937,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) highlights emerging scientific evidence linking persistent viral reservoirs to Long COVID, and emphasizes the potential of its inves...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-highlights-potential-role-of-tvgn-489-on-impact-of-long-covid-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-highlights-potential-role-of-tvgn-489-on-impact-of-long-covid-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2569225790","title":"Tevogen Bio Announces Promising Results for TVGN 489 in Targeting Persistent Viral Reservoirs Linked to Long COVID","url":"https://stock-news.laohu8.com/highlight/detail?id=2569225790","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569225790?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:30","pubTimestamp":1758630629,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. has announced the potential role of its investigational precision T cell therapy, TVGN 489, in addressing Long COVID, a condition affecting an estimated 20 million Americans. Emerging scientific evidence suggests that persistent viral reservoirs contribute to Long COVID, and TVGN 489 is designed to target virus-infected cells by focusing on multiple SARS-CoV-2 proteins across the viral genome. In a proof-of-concept clinical trial, TVGN 489 demonstrated efficacy in reducing viral load and showed persistence for at least six months without interfering with patients' immune responses. The company is preparing for clinical manufacturing of TVGN 489, with ongoing research to further explore its potential in restoring homeostasis in patients with Long COVID.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL1yLyzs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","LU2095319765.USD","TVGN","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","BK4139","IE00B64PRP62.GBP","BK4588","NDAQ","IE00BGHQF748.EUR","LU2210149790.SGD"],"gpt_icon":0},{"id":"2569790270","title":"Tevogen Highlights Potential Role of Tvgn 489 in Eliminating Persistent Viral Reservoirs Linked to Long Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2569790270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569790270?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:30","pubTimestamp":1758630613,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nFWN3VA04X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2568995442","title":"Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans","url":"https://stock-news.laohu8.com/highlight/detail?id=2568995442","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568995442?lang=en_us&edition=fundamental","pubTime":"2025-09-20 03:40","pubTimestamp":1758310800,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Sept.  19, 2025  (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/19/3153373/0/en/Tevogen-Commends-HHS-for-Addressing-Long-COVID-Emphasizes-TVGN-489-s-Potential-Impact-for-20-Million-Americans.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4009","BK4139","TVGN","HHS"],"gpt_icon":0},{"id":"2566983519","title":"Tevogen Bio Holdings Inc.'s CIO to Join Panel at Databricks DATA + AI World Tour in Boston","url":"https://stock-news.laohu8.com/highlight/detail?id=2566983519","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566983519?lang=en_us&edition=fundamental","pubTime":"2025-09-10 23:59","pubTimestamp":1757519953,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. Mehta will discuss Tevogen.AI's application of advanced data and AI technologies, including its PredicTcell platform, developed in collaboration with Microsoft and Databricks, to accelerate precision immunotherapy development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on September 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL64lwBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1145028129.USD","LU0661504455.SGD","LU0949170426.SGD","IE00B7KXQ091.USD","IE00BQXX3C00.GBP","LU1564329032.USD","LU0683600562.USD","IE00BJJMRY28.SGD","LU0738911758.USD","LU2247934214.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0061475181.USD","LU2168564495.EUR","LU1674673691.USD","LU1868837136.USD","LU1868837300.USD","LU0154236417.USD","LU2347655073.USD","IE00BKVL7J92.USD","LU0323239441.USD","LU1153585028.USD","TVGN","BK4612","LU2092937221.SGD","LU0861579265.USD","LU2168564222.USD","SG9999018865.SGD","LU0096364046.USD","LU0061474960.USD","LU0256863902.USD","LU0757359954.USD","LU0238689110.USD","IE0034235303.USD","LU1670711123.USD","SG9999017495.SGD","LU0466842654.USD","LU0426412945.USD","LU2092627202.USD","IE00BQXX3F31.USD","IE000ITXATA3.USD","LU0316494557.USD","LU0894486033.HKD","IE00B775H168.HKD","IE00BMPRXQ63.HKD","LU1267930813.SGD","NDAQ","IE00B5949003.HKD","LU0072461881.USD"],"gpt_icon":1},{"id":"2566835629","title":"Tevogen Cio and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks Data + AI World Tour in Boston","url":"https://stock-news.laohu8.com/highlight/detail?id=2566835629","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566835629?lang=en_us&edition=fundamental","pubTime":"2025-09-10 23:59","pubTimestamp":1757519942,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nTUA3KBB6C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://semperparatusspac.com","stockEarnings":[{"period":"1week","weight":-0.1233},{"period":"1month","weight":-0.2403},{"period":"3month","weight":-0.5133},{"period":"6month","weight":-0.7051},{"period":"1year","weight":-0.6268},{"period":"ytd","weight":-0.5906}],"compareEarnings":[{"period":"1week","weight":0.0069},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0574},{"period":"6month","weight":0.1423},{"period":"1year","weight":0.1263},{"period":"ytd","weight":0.1677}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.026634},{"month":2,"riseRate":0.75,"avgChangeRate":0.093777},{"month":3,"riseRate":0.5,"avgChangeRate":-0.166085},{"month":4,"riseRate":0.5,"avgChangeRate":-0.189171},{"month":5,"riseRate":0.25,"avgChangeRate":0.008552},{"month":6,"riseRate":0.25,"avgChangeRate":-0.034979},{"month":7,"riseRate":0.5,"avgChangeRate":-0.078575},{"month":8,"riseRate":0.5,"avgChangeRate":-0.064152},{"month":9,"riseRate":0.5,"avgChangeRate":-0.105281},{"month":10,"riseRate":0.75,"avgChangeRate":1.418967},{"month":11,"riseRate":0.5,"avgChangeRate":-0.189646},{"month":12,"riseRate":0.5,"avgChangeRate":-0.060495}],"exchange":"NASDAQ","name":"Tevogen Bio Holdings","nameEN":"Tevogen Bio Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tevogen Bio Holdings(TVGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tevogen Bio Holdings,TVGN,Tevogen Bio Holdings股票,Tevogen Bio Holdings股票老虎,Tevogen Bio Holdings股票老虎国际,Tevogen Bio Holdings行情,Tevogen Bio Holdings股票行情,Tevogen Bio Holdings股价,Tevogen Bio Holdings股市,Tevogen Bio Holdings股票价格,Tevogen Bio Holdings股票交易,Tevogen Bio Holdings股票购买,Tevogen Bio Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tevogen Bio Holdings(TVGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}